The recombinant human thyroid-stimulating hormone (rhTSH) can be used for differentiated thyroid cancer (DTC) preparation before ¹³¹I therapy, and follow-up. Since its approval by the American Food and Drug Administration (FDA) in 1998, rhTSH has been clinically used in European countries, the United States, and other countries for nearly 30 years. In April 2024, China’s first independently developed rhTSH agent was approved. Based on clinical experience and evidence from domestic and international studies, an expert consensus on the application of rhTSH has been developed following thorough consultations among experts. The consensus offers evidence-based recommendations to guide the appropriate use of rhTSH in clinical practice.

Objective To investigate DNA excision repair cross-complementing gene-1 (ERCC1) and cyclooxygenase-2 (COX-2) expression levels in gastric cancer (GC) and evaluate the correlation between two proteins. Methods Immunohistochemistry was performed to detect the expression of ERCC1 and COX-2 in 239 GC cases, and analyzed the association between ERCC1 and COX-2 expression levels and clinicopathologic parameters. Results ERCC1 and COX-2 expression levels were significantly correlated with lymph node metastasis (P <0.05), while not associated with tumor size, location, depth of invasion and tumor differentiation (P>0.05). The positive expression rate of COX-2 in GC patients with HP infection was 86.5%, higher than those without HP infection. No correlation was found between two proteins. Conclusion Both ERCC1 and COX-2 were related with tumor progression, which may serve as valuable markers for determining biological behavior in GC. However , they did not show positive interaction.